WO2006083678A2 - β-CYCLODEXTRIN DERIVATIVES AS ANTIBACTERIAL AGENTS - Google Patents

β-CYCLODEXTRIN DERIVATIVES AS ANTIBACTERIAL AGENTS Download PDF

Info

Publication number
WO2006083678A2
WO2006083678A2 PCT/US2006/002801 US2006002801W WO2006083678A2 WO 2006083678 A2 WO2006083678 A2 WO 2006083678A2 US 2006002801 W US2006002801 W US 2006002801W WO 2006083678 A2 WO2006083678 A2 WO 2006083678A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
lower alkyl
aryl
aralkyl
aminoalkyl
Prior art date
Application number
PCT/US2006/002801
Other languages
French (fr)
Other versions
WO2006083678A3 (en
Inventor
Nourredine Fahmi
Frank Werner Schmidtmann
Sidney Hecht
Original Assignee
Pinnacle Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pinnacle Pharmaceuticals, Inc. filed Critical Pinnacle Pharmaceuticals, Inc.
Priority to MX2007010129A priority Critical patent/MX2007010129A/en
Priority to EP06733927A priority patent/EP1846006A4/en
Priority to JP2007553231A priority patent/JP2008528761A/en
Priority to CA002596026A priority patent/CA2596026A1/en
Priority to AU2006211173A priority patent/AU2006211173A1/en
Publication of WO2006083678A2 publication Critical patent/WO2006083678A2/en
Publication of WO2006083678A3 publication Critical patent/WO2006083678A3/en
Priority to IL184844A priority patent/IL184844A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Definitions

  • the invention relates to development of new antibiotics against pathogenic bacteria.
  • the invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance.
  • This new class of antibiotics are derivatives of ⁇ -cyclodextrin ( ⁇ -CD), which is a cyclic molecule comprising seven D-glucose units.
  • compositions comprise one or more members of the compounds disclosed in the invention and a pharmaceutically acceptable carrier.
  • the invention provides methods for using a compound or compounds having the formula:
  • R 2 is H, OH, OAc, OMe, O-lower alkyl, or 0(CH 2 CH 2 O) n ;
  • R 3 is H, OH, OAc, OMe, O-lower alkyl, OSO 3 Na, orNH 2 ;
  • R 6 is H, NH 2 , S(CH 2 ) m NH 2 , 1, N 3 , SH, lower alkyl, S-alkylguanidyl, O-alkylguanidyl, S-aminoalkyl, O-aminoalkyl, aminoalkyl, O- lower alkyl, aralkyl, aryl, heterocyclic ring(s), OSO 3 Na or N which is mono, di or tri- substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N, O or S which can be further substituted with H, alky
  • the invention provides a method for inhibiting the growth of a bacterium. In a further embodiment of this aspect, the invention provides methods for treating a bacterial infection. In a further embodiment of this aspect, the invention provides methods for preventing a bacterial infection.
  • the invention provides methods for potentiating the activity of antibiotics to inhibit the growth of a bacterium which are resistant to clinically used antibiotics, to treat or prevent an infection by these bacteria.
  • the invention relates to development of new antibiotics against pathogenic bacteria.
  • the invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance.
  • This new class of antibiotics are derivatives of ⁇ -cyclodextrin ( ⁇ -CD), which is a cyclic molecule comprising seven D-glucose units.
  • compositions comprise one or more members of the compounds disclosed in the invention and a pharmaceutically acceptable carrier.
  • carrier encompasses any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, or other material well known in the art for use in pharmaceutical formulations. It will be understood that the characteristics of the carrier, excipient, or diluent will depend on the route of administration for a particular application. The preparation of pharmaceutically acceptable formulations containing these materials is described in, e.g., Remington's Pharmaceutical Sciences, 18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, PA, 1990, ISBN: 0-912734-04-3.
  • the invention provides methods for using a compound or compounds of the first and second aspects of the invention as antimicrobial agents.
  • the invention provides a method for inhibiting the growth of a bacterium. The method according to this embodiment of the invention comprises contacting the bacteria with one or more members of a compound having the formula
  • the invention provides methods for treating a bacterial infection.
  • the method according to this embodiment of the invention comprises administering to a mammal with a bacterial infection one or more members of a compound having the formula
  • the term “lower alkyl” means an alkyl group from 1 to 7 carbon atoms.
  • the terms “alkyl” and “aryl” include alkyl or aryl groups which may be substituted or unsubstituted. Preferred substitutions include, without limitation, substitution with nitrogen containing moieties, including amino groups, which may be mono or disubstituted, preferably with alkyl or aryl groups.
  • the term “alkyl” includes chains of 1-7 atoms with one or more nitrogen atoms and the remainder carbon atoms.
  • the invention provides methods for preventing a bacterial infection.
  • the method according to this embodiment of the invention comprises administering to a mammal susceptible to a bacterial infection one or more members of a compound having the formula
  • lower alkyl means an alkyl group from 1 to 7 carbon atoms.
  • alkyl and aryl include alkyl or aryl groups which may be substituted or unsubstituted. Preferred substitutions include, without limitation, substitution with nitrogen containing moieties, including amino groups, which may be mono or disubstituted, preferably with alkyl or aryl groups.
  • alkyl includes chains of 1-7 atoms with one or more nitrogen atoms and the remainder carbon atoms.
  • the invention provides methods for potentiating the activity of antibiotics to inhibit the growth of a bacterium which are resistant to clinically used antibiotics, to treat or prevent an infection by these bacteria.
  • the methods according to this aspect of the invention comprise contacting the bacterium with said antibiotic and one or more members of a compound having the formula
  • R 2 is H, OH, OAc, OMe 5 0-lower alkyl, or 0(CH 2 CH 2 O) n ;
  • R 3 is H, OH, OAc, OMe, 0-lower alkyl, OSO 3 Na 5 or NH 2 ;
  • R 6 is H, NH 2 , S(CH 2 ) m NH 2 , 1 5 N 3 , SH 5 lower alkyl, S-alkylguanidyl, O-alkylguanidyl, S-aminoalkyl, O-aminoalkyl, aminoalkyl, O- lower alkyl, aralkyl, aryl, heterocyclic ring(s), OSO 3 Na or N which is mono, di or tri- substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N, O or S which can be further substituted with H,
  • lower alkyl means an alkyl group from 1 to 7 carbon atoms.
  • alkyl and aryl include alkyl or aryl groups which may be substituted or unsubstituted. Preferred substitutions include, without limitation, substitution with nitrogen containing moieties, including amino groups, which may be mono or disubstituted, preferably with alkyl or aryl groups.
  • alkyl includes chains of 1-7 atoms with one or more nitrogen atoms and the remainder carbon atoms.
  • potentiation may be defined as a circumstance in which a compound substantially lowers the MIC of an antibacterial agent toward one or more organisms. It includes the case in which it effectively restores the therapeutic utility of an antibacterial agent whose utility has been compromised by bacterial resistance.
  • one or more members of compounds of the invention can be administered in combination with any other antibiotic useful for treating the disease or condition that does not diminish the antimicrobial effect of the compound.
  • the term "in combination with” means in the course of treating the same disease in the same patient, and includes administering the compound and an antibiotic in any order, including simultaneous administration, as well as any temporally spaced order, for example, from sequentially with one immediately following the other to up to several days apart.
  • Such combination treatment may also include more than a single administration of the compound, and independently the antibiotic.
  • the administration of the compound and antibiotic may be by the same or different routes.
  • the bacteria is in a mammal.
  • the mammal is a human.
  • administration of the compound can be by any suitable route, including, without limitation, parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal or vaginal.
  • Administration of the therapeutic compositions can be carried out using known procedures at dosages and for periods of time effective to reduce symptoms or surrogate markers of the infection.
  • a doctor can determine the appropriate dose to administer or therapeutic protocol useful for preventing or preventing a bacterial infection. It may be desirable to administer simultaneously, or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention to an individual as a single treatment episode.
  • Methicillin-resistant staphylococcus aureus is a bacterial infection resistant to antibiotic methicillin and can no longer be killed by this antiobiotic.
  • various compounds were used antibiotics to treat Staphylococcus aureus (Methicillin resistant). The results are shown in Table 5 below. These results below demonstrate that compounds of the invention are able to retain activity against Methicillin resistance.
  • Staphylococcus aureus* susceptible
  • Staphylococcus aureus Metal-resistant
  • Compound MIC ⁇ g/mL Compound MIC ⁇ g/mL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance. This new class of antibiotics are derivatives of β-cyclodextrin (β-CD), which is a cyclic molecule comprising seven D-glucose units.

Description

β-CYCLODEXTRIN DERIVATIVES AS
ANTIBACTERIAL AGENTS
(Attorney Docket No. PIN-002PC)
BACKGROUND OF THE INVENTION
Related Applications
This application claims the benefit of U.S. Provisional Patent Application Serial No. 60/647,841, filed on January 28, 2005, the contents of which are incorporated herein by reference in its entirety.
Field of the invention
The invention relates to development of new antibiotics against pathogenic bacteria.
Summary of the related art
Numerous bacteria are known to cause diseases in humans. Among these bacteria are Enterococcus faecium, Eschericia coli, Pseudomonas aeruginosa, Bacillus atrophaeus, Staphylococcus aureus, Salmonella choleraesuis, Bacillus anthrasis, and many others. A disturbing recent trend has been the development of resistance to existing antibiotics in numerous pathogenic bacteria. There is, therefore, a need for new antibiotics for which resistance has not yet emerged. Preferably, such antibiotics should be members of a new class of antibiotics, thus making evolutionary resistance to these antibiotics more difficult.
BRIEF SUMMARY OF THE INVENTION
The invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance. This new class of antibiotics are derivatives of β-cyclodextrin (β-CD), which is a cyclic molecule comprising seven D-glucose units.
In a first aspect, the invention provides a compound having the formula
Figure imgf000003_0001
wherein R2 is H, OH5 OAc, 0-lower alkyl, OMe, or 0(CH2CH2O)n; R3 is H, OH, OAc, O-lower alkyl, OMe, OSO3Na, OrNH2; and R6 is N which is mono, di or tri-substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N, O or S which can be further substituted with H, alkyl, aralkyl or aryl, wherein for each of R2, R3 and R6 any one or more of the carbon atoms may be optionally replaced by S, N or O, and wherein n is from about 1 to about 15, preferably from about 1 to about 10.
In a second aspect the invention provides pharmaceutical compositions. These compositions comprise one or more members of the compounds disclosed in the invention and a pharmaceutically acceptable carrier.
In a third aspect, the invention provides methods for using a compound or compounds having the formula:
Figure imgf000003_0002
wherein R2 is H, OH, OAc, OMe, O-lower alkyl, or 0(CH2CH2O)n; R3 is H, OH, OAc, OMe, O-lower alkyl, OSO3Na, orNH2; and R6 is H, NH2, S(CH2)mNH2, 1, N3, SH, lower alkyl, S-alkylguanidyl, O-alkylguanidyl, S-aminoalkyl, O-aminoalkyl, aminoalkyl, O- lower alkyl, aralkyl, aryl, heterocyclic ring(s), OSO3Na or N which is mono, di or tri- substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N, O or S which can be further substituted with H, alkyl, aralkyl or aryl, wherein for each of R2, R3 and R6 any one or more of the carbon atoms may be optionally replaced by S, N or O, and wherein n is from about 1 to about 15, preferably from about 1 to about 10, and wherein m is from about 1 to about 15, preferable from about 1 to about 10, as antimicrobial agents. In one embodiment of this aspect, the invention provides a method for inhibiting the growth of a bacterium. In a further embodiment of this aspect, the invention provides methods for treating a bacterial infection. In a further embodiment of this aspect, the invention provides methods for preventing a bacterial infection.
In a fourth aspect, the invention provides methods for potentiating the activity of antibiotics to inhibit the growth of a bacterium which are resistant to clinically used antibiotics, to treat or prevent an infection by these bacteria.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The invention relates to development of new antibiotics against pathogenic bacteria. The invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance. This new class of antibiotics are derivatives of β-cyclodextrin (β-CD), which is a cyclic molecule comprising seven D-glucose units.
In a first aspect, the invention provides a compound having the formula
Figure imgf000005_0001
wherein R2 is H, OH, OAc, 0-lower alkyl, OMe, or 0(CH2CH2O)n; R3 is H, OH, OAc3 O-lower alkyl, OMe, OSO3Na, or NH2; and R6 is N which is mono, di or tri-substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N, O or S which can be further substituted with H, alkyl, aralkyl or aryl, wherein for each of R2, R3 and R6 any one or more of the carbon atoms may be optionally replaced by S, N or O, and wherein n is from about 1 to about 15, preferably from about 1 to about 10.
In a second aspect the invention provides pharmaceutical compositions. These compositions comprise one or more members of the compounds disclosed in the invention and a pharmaceutically acceptable carrier.
As used herein, the term "physiologically acceptable" refers to a material that does not interfere with the effectiveness of the compounds of the first or third aspects of the invention and is compatible with a biological system such as a cell, cell culture, tissue, or organism. In certain embodiments, the biological system is a living organism, such as a mammal. In certain embodiments, the mammal is a human.
As used herein, the term "carrier" encompasses any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, or other material well known in the art for use in pharmaceutical formulations. It will be understood that the characteristics of the carrier, excipient, or diluent will depend on the route of administration for a particular application. The preparation of pharmaceutically acceptable formulations containing these materials is described in, e.g., Remington's Pharmaceutical Sciences, 18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, PA, 1990, ISBN: 0-912734-04-3.
In a third aspect, the invention provides methods for using a compound or compounds of the first and second aspects of the invention as antimicrobial agents. In one embodiment of this aspect, the invention provides a method for inhibiting the growth of a bacterium. The method according to this embodiment of the invention comprises contacting the bacteria with one or more members of a compound having the formula
Figure imgf000006_0001
wherein R2 is H, OH, OAc, OMe, O-lower alkyl, or 0(CH2CH2O)n; R3 is H, OH, OAc, OMe, O-lower alkyl, OSO3Na, or NH2; and R6 is H, NH2, S(CH2)mNH2, 1, N3, SH, lower alkyl, S-alkylguanidyl, O-alkylguanidyl, S-aminoalkyl, O-amiηoalkyl, aminoalkyl, O- lower alkyl, aralkyl, aryl, heterocyclic ring(s), OSO3Na or N which is mono, di or tri- substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N, O or S which can be further substituted with H, alkyl, aralkyl or aryl, wherein for each OfR2, R3 and R6 any one or more of the carbon atoms may be optionally replaced by S, N or O, and wherein n is from about 1 to about 15, preferably from about 1 to about 10, and wherein m is from about 1 to about 15, preferable from about 1 to about 10.
For purposes of the invention, the term "lower alkyl" means an alkyl group from 1 to 7 carbon atoms. The terms "alkyl" and "aryl" include alkyl or aryl groups which may be substituted or unsubstituted. Preferred substitutions include, without limitation, substitution with nitrogen containing moieties, including amino groups, which may be mono or disubstituted, preferably with alkyl or aryl groups. Also, for purposes of the invention the term "alkyl" includes chains of 1-7 atoms with one or more nitrogen atoms and the remainder carbon atoms.
In a further embodiment of this aspect, the invention provides methods for treating a bacterial infection. The method according to this embodiment of the invention comprises administering to a mammal with a bacterial infection one or more members of a compound having the formula
Figure imgf000007_0001
wherein R2 is H, OH, OAc, OMe, O-lower alkyl, or 0(CH2CH2O)n; R3 is H, OH, OAc, OMe, O-lower alkyl, OSO3Na3 orNH2; and R6 is H, NH2, S(CH2)mNH2, 1, N3, SH, lower alkyl, S-alkylguanidyl, O-alkylguanidyl, S-aminoalkyl, O-aminoalkyl, aminoalkyl, O- lower alkyl, aralkyl, aryl, heterocyclic ring(s), OSO3Na or N which is mono, di or tri- substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N, O or S which can be further substituted with H, alkyl, aralkyl or aryl, wherein for each of R2, R3 and R6 any one or more of the carbon atoms may be optionally replaced by S, N or O, and wherein n is from about 1 to about 15, preferably from about 1 to about 10, and wherein m is from about 1 to about 15, preferable from about 1 to about 10.
For purposes of the invention, the term "lower alkyl" means an alkyl group from 1 to 7 carbon atoms. The terms "alkyl" and "aryl" include alkyl or aryl groups which may be substituted or unsubstituted. Preferred substitutions include, without limitation, substitution with nitrogen containing moieties, including amino groups, which may be mono or disubstituted, preferably with alkyl or aryl groups. Also, for purposes of the invention the term "alkyl" includes chains of 1-7 atoms with one or more nitrogen atoms and the remainder carbon atoms. In a further embodiment of this aspect, the invention provides methods for preventing a bacterial infection. The method according to this embodiment of the invention comprises administering to a mammal susceptible to a bacterial infection one or more members of a compound having the formula
Figure imgf000008_0001
wherein R2 is H, OH, OAc, OMe, 0-lower alkyl, or 0(CH2CH2O)n; R3 is H, OH, OAc, OMe, 0-lower alkyl, OSO3Na, or NH2; and R6 is H, NH2, S(CH2)mNH2, 1, N3, SH, lower alkyl, S-alkylguanidyl, O-alkylguanidyl, S-aminoalkyl, O-aminoalkyl, aminoalkyl, O- lower alkyl, aralkyl, aryl, heterocyclic ring(s), OSO3Na or N which is mono, di or tri- substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N, O or S which can be further substituted with H, alkyl, aralkyl or aryl, wherein for each of R2, R3 and R6 any one or more of the carbon atoms may be optionally replaced by S, N or O, and wherein n is from about 1 to about 15, preferably from about 1 to about 10, and wherein m is from about 1 to about 15, preferable from about 1 to about 10.
For purposes of the invention, the term "lower alkyl" means an alkyl group from 1 to 7 carbon atoms. The terms "alkyl" and "aryl" include alkyl or aryl groups which may be substituted or unsubstituted. Preferred substitutions include, without limitation, substitution with nitrogen containing moieties, including amino groups, which may be mono or disubstituted, preferably with alkyl or aryl groups. Also, for purposes of the invention the term "alkyl" includes chains of 1-7 atoms with one or more nitrogen atoms and the remainder carbon atoms.
Li the methods according to this aspect of the invention the bacteria is in a mammal. Preferably, the mammal is a human. In the methods according to this aspect of the invention, administration of the compound can be by any suitable route, including, without limitation, parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal or vaginal. Administration of the therapeutic compositions can be carried out using known procedures at dosages and for periods of time effective to reduce symptoms or surrogate markers of the infection. A doctor can determine the appropriate dose to administer or therapeutic protocol useful for preventing or preventing a bacterial infection. It may be desirable to administer simultaneously, or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention to an individual as a single treatment episode.
In a fourth aspect, the invention provides methods for potentiating the activity of antibiotics to inhibit the growth of a bacterium which are resistant to clinically used antibiotics, to treat or prevent an infection by these bacteria. The methods according to this aspect of the invention comprise contacting the bacterium with said antibiotic and one or more members of a compound having the formula
Figure imgf000009_0001
wherein R2 is H, OH, OAc, OMe5 0-lower alkyl, or 0(CH2CH2O)n; R3 is H, OH, OAc, OMe, 0-lower alkyl, OSO3Na5 or NH2; and R6 is H, NH2, S(CH2)mNH2, 15 N3, SH5 lower alkyl, S-alkylguanidyl, O-alkylguanidyl, S-aminoalkyl, O-aminoalkyl, aminoalkyl, O- lower alkyl, aralkyl, aryl, heterocyclic ring(s), OSO3Na or N which is mono, di or tri- substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N, O or S which can be further substituted with H, alkyl, aralkyl or aryl, wherein for each of R2, R3 and R6 any one or more of the carbon atoms may be optionally replaced by S, N or O, and wherein n is from about 1 to about 15, preferably from about 1 to about 10, and wherein m is from about 1 to about 15, preferable from about 1 to about 10. For purposes of the invention, the term "lower alkyl" means an alkyl group from 1 to 7 carbon atoms. The terms "alkyl" and "aryl" include alkyl or aryl groups which may be substituted or unsubstituted. Preferred substitutions include, without limitation, substitution with nitrogen containing moieties, including amino groups, which may be mono or disubstituted, preferably with alkyl or aryl groups. Also, for purposes of the invention the term "alkyl" includes chains of 1-7 atoms with one or more nitrogen atoms and the remainder carbon atoms.
For purposes of the invention, the term "resistant" or "resistance" to a bacterium or bacterial infection to an antibiotic includes a complete resistance to the antibiotic or a partial resistance which is defined herein as a circumstance in which the MIC of an antibiotic toward the organism in question has increased.
For purposes herein, potentiation may be defined as a circumstance in which a compound substantially lowers the MIC of an antibacterial agent toward one or more organisms. It includes the case in which it effectively restores the therapeutic utility of an antibacterial agent whose utility has been compromised by bacterial resistance.
In any of the methods according to the invention, one or more members of compounds of the invention can be administered in combination with any other antibiotic useful for treating the disease or condition that does not diminish the antimicrobial effect of the compound. For purposes of this aspect of the invention, the term "in combination with" means in the course of treating the same disease in the same patient, and includes administering the compound and an antibiotic in any order, including simultaneous administration, as well as any temporally spaced order, for example, from sequentially with one immediately following the other to up to several days apart. Such combination treatment may also include more than a single administration of the compound, and independently the antibiotic. The administration of the compound and antibiotic may be by the same or different routes.
hi the methods according to this aspect of the invention the bacteria is in a mammal. Preferably, the mammal is a human. In the methods according to this aspect of the invention, administration of the compound can be by any suitable route, including, without limitation, parenteral, oral, sublingual, transdermal, topical, intranasal, aerosol, intraocular, intratracheal, intrarectal or vaginal. Administration of the therapeutic compositions can be carried out using known procedures at dosages and for periods of time effective to reduce symptoms or surrogate markers of the infection. A doctor can determine the appropriate dose to administer or therapeutic protocol useful for preventing or preventing a bacterial infection. It may be desirable to administer simultaneously, or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention to an individual as a single treatment episode.
In certain aspects of the methods according to the invention, it is desirable to have antibiotics with a relatively broad spectrum, so that a variety of different bacterial infection can be treated. In other aspects, such as protection against bioterrorism, it may be desirable to have antibiotics with a narrow spectrum, specific for likely bioterrorism organisms, so that protection from the bacteria may be obtained while preserving the normal flora in the body. The invention provides methods for achieving each of these goals.
The following examples are intended to further illustrate certain particularly preferred embodiments of the invention and are not intended to limit the scope of the invention.
Example 1 Bacterial growth standardization
One to three colonies of bacteria were picked from an Mueller-Hinton or Brain Heart infusion agar plate (depending on the bacterial strain) and transferred to 3 ml Mueller-Hinton broth or Brain Heart infusion media (depending on the bacterial strain). Bacteria were allowed to grow for 2-4 hours in an incubator at 37° C. Bacteria- inoculated media were dispersed in 0.9% saline to match McFarland standard density. 100 μl standardized inoculation was added to 20 ml media (dilution 1). 10 μl of the new dilution was added to 990 μl media and mixed (dilution 2). 10 μl of dilution 2 was spread on an agar plate and allowed to grow overnight. Colonies were then plated.
Example 2
Bacterial panel testing
Test compound was diluted to 10 μg/ml in dimethylsulfoxide. Four μl of diluted test compound was loaded into column 2 of a 96 well NUNC microplate, as shown in Table 1 below. Four μl of Rifampicin antibiotic was loaded into row H, column 2.
Table 1 : 96 well NUNC microplate set-up, Concentration in μg/ml
Figure imgf000012_0001
All wells were then filled with 100 μl of inoculated media (dilution 1 from Example 1). A further 100 μl of the inoculated media was then added to column 2 and the contents are pipetted to thoroughly mix the contents. A foil 100 μl was then transferred from column 2 and mixed into column 3. This process was continued from left to right until columns 2-12 were serially diluted, and the final draw from column 12 was discarded. The plates were covered with 3M sealing tape (plates containing Enterococcus faecium were sealed with Air Pore sealing tape) and allowed to grow for 20-24 hours. Cytotoxic wells (clear wells) are then scored and the potency of the compound was determined. The results are shown in Table 2 below. These results show that while some compounds were inactive, others demonstrated either broad spectrum or narrow spectrum activity.
Table 2: Activity of test compounds (MICs in μg/mL)
Figure imgf000013_0001
>200 >200 >200 >200 200-100 >200 690
>200 >200 >200 >200 50-25 >200 215
>200 >200 >200 >200 25-12.5 >200 >2000
>200 >200 >200 >200 25-12.5 >200 510
>200 >200 >200 >200 200-100 >200 755
>200 100-50 >200 >200 200-100 >200 780
>200 3.12-1.56 50-25 25-12.5 1.56-0.78 50-25 840
>200 >200 >200 >200 >200 >200 193
Figure imgf000014_0001
>200 >200 >200 >200 >200 >200 144
>200 >200 >200 >200 <0.2 >200
>200 50-25 >200 >200 100-50 >200 2116
>200 >200 >200 >200 200-100 >200
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 100-50 >200
>200 >200 >200 >200 25-12.5 >200 524
>200 >200 >200 >200 200-100 >200
Figure imgf000015_0001
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 50-25 >200
Figure imgf000016_0001
HCl
>200 >200 25-12.5 50-25 1.56-0.78 >200 321
Figure imgf000016_0002
>200 >200 >200 >200 25-12.5 >200 2990
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 12.5-6.25 >200
>200 >200 >200 >200 >200 >200
Figure imgf000016_0003
PP5032
Figure imgf000016_0004
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 25-12.5 >200 480
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 200-100 >200
>200 >200 >200 >200 >200 >200
>200 >200 100-50 50-25 25-12.5 >200
100-50 >200 >200 >200 50-25 >200 860
Figure imgf000017_0001
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 >200 >200
>200 200-100 100-50 200-100 12.5-6.25
>200 >200 >200 >200 50-25
>200 50-25 100-50 >200 6.25-3.12
>200 >200 >200 >200 100-50
Figure imgf000018_0001
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 12.5-6.25 >200
>200 >200 >200 >200 25-12.5 >200
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 >200 >200
Figure imgf000019_0001
200-100 >200 >200 >200 >200 >200
>200 >200 >200 >200 200-100 >200
>200 >200 >200 >200 100-50 >200
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 200-100 >200
>200 >200 >200 >200 >200 >200
Figure imgf000020_0001
>200 200-100 100-50 200-100 100-50 >200
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 >200 >200
>200 3.12-1.56 25-12.5 12.5-6.25 1.56-0.78 6.25-3.12 43
Figure imgf000021_0001
>200 >200 >200 >200 >200 >200
>200 6.25-3.12 200-100 100-50 1.56-0.78 6.25-3.12 127
>200 3.12-1.56 50-25 50-25 1.56-0.78 6.35-3.12 129
>200 6.25-3.12 50-25 100-50 6.25-3.12 6.25-3.12 123
>200 100-50 >200 >200 50-25 200-100
>200 12.5-6.25 >200 >200 6.25-3.12 12.5-6.25 398
>200 >200 >200 >200 >200 >200
Figure imgf000022_0001
>200 >200 >200 >200 100-50 >200
>200 25-12.5 >200 >200 12.5-6.25 25-12.5 317
>200 >200 >200 >200 12.5-6.25 50-25
>200 200-100 >200 >200 50-25 >200
>200 12.5-6.25 200-100 >200 6.25-3.12 >200
>200 50-25 >200 >200 50-25 100-50
>200 >200 >200 >200 >200 >200
Figure imgf000023_0001
>200 200-100 >200 >200 >200 >200
>200 200-100 >200 >200 >200 >200
>200 6.25-3.12 >200 >200 3.12-1.56 12.5-6.25
>200 3.12-1.56 100-50 100-50 3.12-1.56 1.56-0.78
>200 >200 >200 >200 >200 >200
>200 12.5-6.25 >200 >200 6.25-3.12 100-50
>200 3.12-1.56 >200 100-50 1.56-0.78 25-12.5 378
Figure imgf000024_0001
5 376
Figure imgf000025_0001
>200 >200 >200 >200 200-100 >200
>200 12.5-6.25 25-12.5 25-12.5 6.25-3.12 25-12.5 105
>200 12.5-6.25 >200 100-50 6.25-3.12 25-12.5
>200 12.5-6.25 >200 >200 12.5-6.25 25-12.5
>200 12.5-6.25 >200 >200 6.25-3.12 25-12.5
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 12-5-6.25 >200
Figure imgf000026_0001
100-50 >200 >200 >200 >200 >200 109.3
100-50 >200 200-100 50-25 6.25-3.12 >200 56.2
200-100 200-100 >200 50-25 6.25-3.12 >200 54.3
>200 >200 >200 >200 >200 >200
>200 6.25-3.12 >200 200-100 3.12-1.56 100-50 373
>200 6.25-3.12 200-100 100-50 3.12-1.56 100-50 282
>200 >200 >200 >200 200-100 >200
Figure imgf000027_0001
>200 >200 >200 >200 >200 >200
>200 >200 >200 >200 50-25 >200 589
>200 6.25-3.12 25-12.5 25-12.5 3.12-1.56 50-25 297
>200 6.25-3.12 >200 200-100 3.12-1.56 200-100 297
200-100 >200 >200 >200 50-25 >200
>200 3.12-1.56 100-50 50-25 3.12-1.56 12.5-6.25
>200 12.5-6.25 100-50 200-100 25-12.5 12.5-6.25
Figure imgf000028_0001
>200 6.25-3.12 100-50 200-100 12.5-6.25 6.25-3.12
>200 >200 >200 100-50 50-25 >200
>200 200-100 >200 >200 12.5-6.25 >200
>200 6.25-3.12 >200 100-50 6.25-3.12 6.25-3.12
>200 12.5-6.25 >200 >200 12.5-6.25 12.5-6.25
>200 100-50 >200 >200 50-25 >200
Figure imgf000029_0001
6.25-3.12 25-12.5 3.12-1.56 3.12-1.56 1.56-0.78 100-50
25-12.5 12.5-6.25 6.25-3.12 6.25-3.12 6.25-3.12 12.5-6.25
100-50 25-12.5 25-12.5 25-12.5 12.5-6.25 50-25 32.4
>200 12.5-6.25 200-100 200-100 3.12-1.56 >200
12.5-6.25 12.5-6.25 200-100 >200 12.5-6.25 12.5-6.25
>100 >100 >100 >100 100-50 >100
Figure imgf000030_0001
>200 >200 >200 >200 >200 >200
>100 25-12.5 50-25 50-25 3.12-1.56 >100 193.5
>200 >200 >200 100-50 12.5-6.25 >200
Figure imgf000031_0001
PPS14S
* Lung cancer cells A549
Example 3 Potentiation of Clinically Used Antibiotics by Compounds vs.
Clinical Isolates of Pseudomonas aeruginosa
Numerous pathogenic bacteria have developed a resistance to many clinically used antibiotics. Following the protocols described herein, various compounds were mixed with clinically used antibiotics to treat Pseudomonas aeruginosa (P. aeruginosa). The results are shown in Tables 3 and 4 below. These results demonstrate that compounds of the invention are able to potentiate the activity of known antibiotics.
Table 3: Activity of known antibiotics alone or in combination with compounds of the invention
Test Compounds P. aeruginosa (susceptible clinical isolate)
Methicillin >100 Methicillin + PP5027 25-12.5 Methicillin + PP5114 25-12.5 Methicillin + PP5135 6.25-3.12 Methicillin + PP5140 100-50
Penicillin V >100 Penicillin V + PP5027 50-25
Penicillin V + PP5114 50-25
Penicillin V + PP5135 25-12.5
Penicillin V + PP5140 50-25
Vancomycin >100
Vancomycin + PP5027 12.5-6.25
Vancomycin + PP5114 25-12.5
Vancomycin + PP5135 3.12-1.56
Vancomycin + PP5140 100-50
Table 4: Activity of known antibiotics alone or in combination with compounds of the invention (AG = Aminoglycoside)
MIC μg/mL
Susceptible A G Resistant Multi-drug Resistant
Chloramphenicol 50-25 50-25 100-50
Chloramphenicol + PP5027 01.56-0.78 0.2-0.1 100-50
Chloramphenicol + PP5113 3.12-1.56 12.5-6.25 12.5-6.25
Chloramphenicol + PP5114 6.25-3.12 6.25-3.12 12.5-6.25
Chloramphenicol + PP5115 50-25 3.12-1.56 12.5-6.25
Chloramphenicol + PP5121 50-25 50-25 100-50
Norfloxacin 6.25-3.12 1.56-0.78 >100
Norfloxacin + PP5027 3.12-1.56 <0.1 >100
Norfloxacin + PP5113 0.78-0.39 0.78-0.39 >100
Norfloxacin + PP5114 0.78-0.39 0.2-0.1 >100
Norfloxacin + PP5115 6.25-3.12 3.12-1.56 >100
Norfloxacin + PP5121 6.25-3.12 1.56-0.78 >100
Tobramycin 0.39-0.2 12.5-6.25 >100
Tobramycin + PP5027 0.78-0.39 0.2-0.1 >100 Tobramycin + PP5113 <0.1 25-12.5 100-50
Tobramycin + PP5114 <0.1 3.12-1.56 >100
Tobramycin + PP5115 <0.1 3.12-1.56 >100
Tobramycin + PP5121 0.39-0.2 12.5-6.25 >100
Example 4
Compounds Retain Activity Against Methicillin Resistant Methicillin-resistant staphylococcus aureus is a bacterial infection resistant to antibiotic methicillin and can no longer be killed by this antiobiotic. Following the protocols described herein, various compounds were used antibiotics to treat Staphylococcus aureus (Methicillin resistant). The results are shown in Table 5 below. These results below demonstrate that compounds of the invention are able to retain activity against Methicillin resistance.
Table 5: Activity of compounds against Methicillin Resistance
Staphylococcus aureus* (susceptible) Staphylococcus aureus (Methicillin resistant) Compound MIC μg/mL Compound MIC μg/mL
PP5073 3.12-1.56 PP5073 3.12-1.56
PP5094 3.12-1.56 PP5094 3.12-1.56
PP5098 3.12-1.56 PP5098 6.25-3.12
PP5105 3.12-1.56 PP5105 3.12-1.56
PP5125 3.12-1.56 PP5125 6.25-3.12
* ATCC 700698

Claims

What is claimed is:
1. A compound having the formula
Figure imgf000034_0001
wherein R2 is H, OH, OAc, O-lower alkyl, OMe, or 0(CH2CH2O)n; R3 is H, OH, OAc, O-lower alkyl, OMe, OSO3Na, or NH2; and R6 is N which is mono, di or tri- substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N, O or S which can be further substituted with H, alkyl, aralkyl or aryl,
2. The compound according to claim 1, wherein n is from about 1 to about 10.
3. The compound according to claim 1, wherein for each of R2, R3 and R6 any one or more of the carbon atoms may be optionally replaced by S, N or O.
4. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
5. A method for inhibiting the growth of a bacterium, comprising contacting the bacterium with a compound having the formula
Figure imgf000034_0002
wherein R2 is H5 OH, OAc5 OMe5 O-lower alkyl, or 0(CH2CH2O)n; R3 is H, OH, OAc5 OMe5 O-lower alkyl, OSO3Na5 or NH2; and R6 is H5 NH2, S(CH2)raNH2, 1, N3, SH5 lower alkyl, S-alkylguanidyl5 O-alkylguanidyl, S-aminoalkyl5 O- aminoalkyl, aminoalkyl, O-lower alkyl, aralkyl, aryl, heterocyclic ring(s), OSO3Na or N which is mono, di or tri-substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N5 O or S which can be further substituted with H5 alkyl, aralkyl or aryl.
6. The method according to claim 5, wherein n is from about 1 to about 10, and wherein m is from about 1 to about 10.
7. The method according to claim 5, wherein for each of R2, R3 and R6 any one or more of the carbon atoms may be optionally replaced by S, N or O.
8. The method according to claim 5, wherein the bacterium is in a mammal.
9. The method according to claim 7, wherein the mammal is a human.
10. A method for treating a bacterial infection, comprising administering to a mammal with a bacterial infection a compound having the formula
Figure imgf000035_0001
wherein R2 is H, OH5 OAc5 OMe, O-lower alkyl, or 0(CH2CH2O)n; R3 is H, OH, OAc, OMe, O-lower alkyl, OSO3Na, or NH2; and R6 is H, NH2, S(CH2)mNH2, 1, N3, SH, lower alkyl, S-alkylguanidyl, O-alkylguanidyl, S-aminoalkyl, O- aminoalkyl, aminoalkyl, O-lower alkyl, aralkyl, aryl, heterocyclic ring(s), OSO3Na or N which is mono, di or tri-substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N, O or S which can be further substituted with H, alkyl, aralkyl or aryl.
11. The method according to claim 10, wherein n is from about 1 to about 10, and wherein m is from about 1 to about 10.
12. The method according to claim 10, wherein for each of R2, R3 and R6 any one or more of the carbon atoms may be optionally replaced by S, N or O.
13. The method according to claim 10, wherein the mammal is a human.
14. A method for preventing a bacterial infection, comprising administering to a mammal susceptible to a bacterial infection a compound having the formula
Figure imgf000036_0001
wherein R2 is H, OH, OAc, OMe, O-lower alkyl, or 0(CH2CH2O)n; R3 is H, OH, OAc, OMe, O-lower alkyl, OSO3Na, or NH2; and R6 is H, NH2, S(CH2)mNH2, 1, N3, SH, lower alkyl, S-alkylguanidyl, O-alkylguanidyl, S-aminoalkyl, O- aminoalkyl, aminoalkyl, O-lower alkyl, aralkyl, aryl, heterocyclic ring(s), OSO3Na or N which is mono, di or tri-substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N, O or S which can be further substituted with H, alkyl, aralkyl or aryl.
15. The method according to claim 14, wherein n is from about 1 to about 10, and wherein m is from about 1 to about 10.
16. The method according to claim 14, wherein for each of R2, R3 and R6 any one or more of the carbon atoms may be optionally replaced by S5 N or O.
17. The method according to claim 14, wherein the mammal is a human.
18. A method for potentiating the activity of antibiotic to inhibit the growth of a bacterium which is resistant to said antibiotic, comprising contacting the bacterium with said antibiotic and a compound having the formula
Figure imgf000037_0001
wherein R2 is H, OH, OAc, OMe, O-lower alkyl, or 0(CH2CH2O)n; R3 is H, OH, OAc, OMe, 0-lower alkyl, OSO3Na, OrNH2; and R6 is H, NH2, S(CH2)mNH2, 1, N3, SH, lower alkyl, S-alkylguanidyl, O-alkylguanidyl, S-aminoalkyl, O- aminoalkyl, aminoalkyl, O-lower alkyl, aralkyl, aryl, heterocyclic ring(s), OSO3Na or N which is mono, di or tri-substituted with alkyl, aralkyl, aryl, heterocyclic ring or heterocyclic alkyl, and any of which substituents can be further substituted with N, O or S which can be further substituted with H, alkyl, aralkyl or aryl.
19. The method according to claim 18, wherein n is from about 1 to about 10, and wherein m is from about 1 to about 10.
20. The method according to claim 18, wherein for each of R2, R3 and R6 any one or more of the carbon atoms may be optionally replaced by S, N or O.
21. The method according to claim 18, wherein the bacterium is in a mammal.
22. The method according to claim 21 , wherein the mammal is a human.
PCT/US2006/002801 2005-01-28 2006-01-27 β-CYCLODEXTRIN DERIVATIVES AS ANTIBACTERIAL AGENTS WO2006083678A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MX2007010129A MX2007010129A (en) 2005-01-28 2006-01-27 ??-cyclodextrin derivatives as antibacterial agents.
EP06733927A EP1846006A4 (en) 2005-01-28 2006-01-27 Beta-cyclodextrin derivatives as antibacterial agents
JP2007553231A JP2008528761A (en) 2005-01-28 2006-01-27 Β-cyclodextrin derivatives as antibacterial agents
CA002596026A CA2596026A1 (en) 2005-01-28 2006-01-27 .beta.-cyclodextrin derivatives as antibacterial agents
AU2006211173A AU2006211173A1 (en) 2005-01-28 2006-01-27 Beta-cyclodextrin derivatives as antibacterial agents
IL184844A IL184844A0 (en) 2005-01-28 2007-07-26 ??-cyclodextrin derivatives as antibacterial agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64784105P 2005-01-28 2005-01-28
US60/647,841 2005-01-28

Publications (2)

Publication Number Publication Date
WO2006083678A2 true WO2006083678A2 (en) 2006-08-10
WO2006083678A3 WO2006083678A3 (en) 2006-12-14

Family

ID=36777776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002801 WO2006083678A2 (en) 2005-01-28 2006-01-27 β-CYCLODEXTRIN DERIVATIVES AS ANTIBACTERIAL AGENTS

Country Status (12)

Country Link
US (2) US7737132B2 (en)
EP (1) EP1846006A4 (en)
JP (1) JP2008528761A (en)
KR (1) KR20070101347A (en)
CN (1) CN101151037A (en)
AU (1) AU2006211173A1 (en)
CA (1) CA2596026A1 (en)
IL (1) IL184844A0 (en)
MX (1) MX2007010129A (en)
RU (1) RU2007133709A (en)
WO (1) WO2006083678A2 (en)
ZA (1) ZA200706191B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2061445A2 (en) * 2006-08-30 2009-05-27 Research Foundation of the City University of New York Antimicrobial compositions
WO2013027040A1 (en) * 2011-08-22 2013-02-28 Isis Innovation Limited Cyclic oligosaccharides for use in the treatment and prevention of bacterial infection
WO2018051903A1 (en) 2016-09-13 2018-03-22 国立大学法人名古屋工業大学 Sugar derivative or salt thereof, and antibacterial agent or antibacterial activity enhancer using same
KR101967326B1 (en) * 2017-10-30 2019-08-13 한남대학교 산학협력단 Cationic cyclodextrin derivatives and drug delivery system using thereof
TWI774079B (en) * 2020-10-05 2022-08-11 逢興生物科技股份有限公司 Use of cyclodextrin for manufacturing a composition for inhibiting growth of oral bacteria

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851457B2 (en) * 2004-01-29 2010-12-14 Innovative Biologics, Inc. β-Cyclodextrin derivatives
WO2006075580A1 (en) * 2005-01-13 2006-07-20 National University Corporation Nagoya Institute Of Technology Antibacterial substances injuring bacterial cell membarane and methods of using the same
CA2596026A1 (en) * 2005-01-28 2006-08-10 Pinnacle Pharmaceuticals, Inc. .beta.-cyclodextrin derivatives as antibacterial agents
WO2009058327A1 (en) * 2007-10-30 2009-05-07 Pinnacle Pharmaceuticals, Inc. Cyclodextrin derivatives as potentiators for antibiotics
JP5364923B2 (en) * 2009-01-28 2013-12-11 学校法人福岡大学 Multifunctional cyclodextrin derivatives, clathrate compounds thereof, and production methods thereof.
WO2012151445A1 (en) * 2011-05-03 2012-11-08 Innovative Biologics, Inc. DERIVATIVES OF α-, β- AND γ-CYCLODEXTRIN AND THEIR USE AS ANTI-INFECTIVES
EP2690105A1 (en) * 2012-07-24 2014-01-29 Centre National De La Recherche Scientifique Mannose derivatives, a process for preparing the same and their uses as a drug
JP6249208B2 (en) * 2012-10-31 2017-12-20 国立大学法人 名古屋工業大学 Sugar derivative and antibacterial agent using the same
CN103497275B (en) * 2013-08-09 2015-12-23 华北电力大学（保定） A kind of antibacterial, antiviral guanidinesalt star polymer and its preparation method and application
JP6624422B2 (en) * 2014-07-25 2019-12-25 国立大学法人 名古屋工業大学 Sugar derivatives or salts thereof, antibacterial agents or antibacterial activity enhancers using them, reagents for synthesizing them, and methods for producing these using reagents
CN106734046A (en) * 2015-11-20 2017-05-31 南京科技职业学院 A kind of coking sludge method for innocent treatment
WO2018127819A1 (en) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
EP3600338A4 (en) 2017-03-28 2020-10-28 The University of North Carolina at Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
JP2021515083A (en) * 2018-03-06 2021-06-17 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ Nitric oxide-releasing cyclodextrin as a biodegradable antibacterial scaffold and related methods
CA3124673A1 (en) 2018-12-28 2020-07-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto
CN112516003A (en) * 2020-12-18 2021-03-19 上海杜可生物科技有限公司 Use of cyclodextrin for inhibiting growth of oral bacteria
US11856953B2 (en) 2021-03-11 2024-01-02 Nano And Advanced Materials Institute Limited Launderable bactericidal and virucidal fabric finish
CN116284506B (en) * 2023-03-22 2023-12-08 江南大学 Gamma-cyclodextrin-geraniol derivative and preparation method and application thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576017A (en) * 1897-01-26 Game-counter
JPS5211348B2 (en) 1972-12-23 1977-03-30
JPS5311000B2 (en) 1974-04-18 1978-04-18
DE2425663A1 (en) 1974-05-28 1975-12-04 Tanabe Seiyaku Co 6-(di) methylamino substd. cyclodextrin derivs - hypolipaemics prepd. from cyclodextrin, alkaryl sulphonyl chloride and (di) methylamine
JPS51142088A (en) 1975-05-29 1976-12-07 Tanabe Seiyaku Co Ltd Aminocyclodextrin derivatives and their prepapation.
JPS52138580A (en) * 1976-05-14 1977-11-18 Tanabe Seiyaku Co Ltd Cyclodextrin derivatives
JPS5349089A (en) 1976-10-15 1978-05-04 Tanabe Seiyaku Co Ltd Cyclic polysaccaride compounds and their preparatin
US4258180A (en) 1979-11-05 1981-03-24 American Cyanamid Company C6-Modified cyclodextrin sulfate salts as complement inhibitors
US4247535A (en) 1979-11-05 1981-01-27 American Cyanamid Company Modified cyclodextrin sulfate salts as complement inhibitors
JPS63117003A (en) * 1986-10-31 1988-05-21 Agency Of Ind Science & Technol Cyclodextrin derivative, ultrathin organic film prepared therefrom and its production
DE3710569A1 (en) * 1986-10-31 1988-05-19 Agency Ind Science Techn Cyclodextrin compound, ultrathin film using it, and process for the preparation
JPS63144329A (en) * 1986-12-09 1988-06-16 Agency Of Ind Science & Technol Organic hyper thin film of inclusion compound of dye and cyclodextrin derivative and its production
JPH0375634A (en) 1989-08-17 1991-03-29 Agency Of Ind Science & Technol Optical recording medium
DE69104877T2 (en) 1990-03-15 1995-03-16 Tanabe Seiyaku Co Polysulfate of a cyclodextrin derivative and process for its preparation.
JPH04136001A (en) * 1990-09-27 1992-05-11 Tanabe Seiyaku Co Ltd Polysulfuric ester of sulfonamide derivative of beta-cyclodextrin and preparation thereof
JPH04227602A (en) * 1990-03-15 1992-08-17 Tanabe Seiyaku Co Ltd Polysulfide of amino-beta-cyclodextrin derivative and its production
JPH04226502A (en) * 1990-09-27 1992-08-17 Tanabe Seiyaku Co Ltd Polysulfate of acylaminocyclodextrin derivative and its production
FR2669535A1 (en) 1990-11-26 1992-05-29 Medgenix Group Sa Use of polysulphonated macromolecules as a medicament
FR2681868A1 (en) * 1991-09-30 1993-04-02 Sederma Sa New amphiphilic substances derived from cyclodextrins and their use in cosmetic compositions
DE4136325A1 (en) 1991-11-05 1993-05-13 Hoechst Ag New cyclodextrin derivs. used as bile acid adsorption agents - useful for treating hyperlipidaemia, can be administered at lower does than cholestyramine or colestipol resin
HUT63704A (en) 1991-11-20 1993-09-28 Forte Fotokemiai Ipar Method for accelerating development of photo-materials
JPH0665307A (en) 1992-06-17 1994-03-08 Sankyo Co Ltd Cyclodextrin derivative
ES2053399B1 (en) 1993-01-11 1995-02-16 Univ Madrid Complutense PROCEDURE TO OBTAIN BETA-CYCLODEXTRIN DERIVATIVES.
US5959089A (en) 1993-07-19 1999-09-28 Hannessian; Stephen Amino-cyclodextrin syntheses
US5599912A (en) 1993-09-10 1997-02-04 Coretech, Inc. Compounds and methods for suppressing an immune response to sulfomethoxozale containing substances
GB9325330D0 (en) 1993-12-10 1994-02-16 Univ Toronto Fluorocyclodextrin drug delivery system
FR2713934B1 (en) 1993-12-22 1996-01-12 Commissariat Energie Atomique Use of amino cyclodextrins for the aqueous solubilization of hydrophobic compounds, in particular of pharmaceutically active molecules.
FR2714067B1 (en) 1993-12-22 1996-01-12 Commissariat Energie Atomique New cyclodextrin derivatives, usable in particular for solubilizing hydrophobic chemical compounds such as drugs, and their preparation process.
DE4418842A1 (en) 1994-05-30 1995-12-07 Hoechst Ag Colourless, thermostable, non-toxic cyclised oligo- or poly:saccharide use as charge controller or enhancer
DE4429229A1 (en) 1994-08-18 1996-02-22 Consortium Elektrochem Ind Cyclodextrin derivatives with at least one nitrogen-containing heterocycle, their production and use
DE19517034A1 (en) 1995-05-10 1996-11-14 Hoechst Ag Use of inclusion compounds of ring-shaped polysaccharides as charge control agents
DE19520967A1 (en) 1995-06-08 1996-12-12 Consortium Elektrochem Ind Treatment of leather, synthetic or natural textiles
DE19520989A1 (en) 1995-06-08 1996-12-12 Consortium Elektrochem Ind Polymer with covalently bound reactive cyclodextrin with N-heterocycle
FR2736056B1 (en) 1995-06-29 1997-08-08 Commissariat Energie Atomique CYCLODEXTRIN DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR INCORPORATING HYDROPHOBIC MOLECULES IN ORGANIZED SURFACTANT SYSTEMS
US5834446A (en) 1996-06-21 1998-11-10 Queen's University At Kingston Nerve process growth modulators
JPH1060006A (en) 1996-08-27 1998-03-03 Kikkoman Corp Production of nonreduced-terminal azidized acetylmaltooligosyl bromide
FR2767834B1 (en) 1997-08-29 1999-12-03 Inst Francais Du Petrole MONO AND DI-DERIVATIVES OF CYCLODEXTRINS, THEIR SYNTHESIS AND PURIFICATION AND THEIR SUPPORT
US6180356B1 (en) 1998-03-06 2001-01-30 The Research Foundation Of State University Of Ny Membrane pore inhibiting agents for treating infection
FR2776666B1 (en) 1998-03-31 2002-09-06 Commissariat Energie Atomique COMPLEXES OF INCLUSION IN CYCLODEXTRINS OF ORGANIC ISOTHIOCYANATES, IN PARTICULAR BACTERIOSTATICS, BACTERICIDES AND / OR FUNGICIDES OR THEIR NATURAL PRECURSORS, AND THEIR PREPARATION
FR2792942B1 (en) 1999-04-29 2001-06-08 Commissariat Energie Atomique AMPHIPHILIC CYCLODEXTRINS, THEIR PREPARATION AND THEIR USE FOR SOLUBILIZING ORGANIZED SYSTEMS AND INCORPORATING HYDROPHOBIC MOLECULES
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
CA2406823A1 (en) 2000-04-28 2001-11-08 Lawrence John Penkler Amphiphilic macrocyclic derivatives and their analogues
SG114468A1 (en) 2000-06-23 2005-09-28 Univ Singapore Separation materials for chromatography and electrophoresis applications comprising cyclodextrins cross-linked and chemically bonded to a support via urethane linkages
AU2002246302A1 (en) 2001-03-23 2002-10-08 University College Dublin Macrocyclic oligosaccharide derivatives which form manoscale assemblies
DE60135540D1 (en) 2001-03-27 2008-10-09 Samsung Electronics Co Ltd noporen
US6632748B2 (en) 2001-03-27 2003-10-14 Samsung Electronics Co., Ltd. Composition for preparing substances having nano-pores
FR2843397B1 (en) 2002-08-06 2004-10-15 Chelator NOVEL CYCLODEXTRIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS
KR100533538B1 (en) 2002-12-03 2005-12-05 삼성전자주식회사 Compsoition for Preparing Porous Interlayer Dielectric Thin Film, Containing Novel Pore-Generating Material
JP4675233B2 (en) 2003-03-27 2011-04-20 ナノデックス株式会社 New cyclodextrin derivatives
FR2852959B1 (en) 2003-03-28 2008-02-15 Centre Nat Rech Scient NOVEL CYCLODEXTRIN DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE IN PARTICULAR FOR SOLUBILIZING PHARMACOLOGICALLY ACTIVE SUBSTANCES
WO2005011710A1 (en) * 2003-07-28 2005-02-10 The Board Of Trustees Of The University Of Illinois Per-6-aminosubstituted-deoxy-cyclodextrins to treat alzheimer’s diseases
FR2861396B1 (en) 2003-10-24 2005-12-16 Commissariat Energie Atomique AMPHIPHILIC DERIVATIVES OF CYCLODEXTRINS, PROCESS FOR PREPARING THEM AND USES THEREOF
US7851457B2 (en) * 2004-01-29 2010-12-14 Innovative Biologics, Inc. β-Cyclodextrin derivatives
JP2005290066A (en) 2004-03-31 2005-10-20 Nihon Hels Industry Corp Cyclodextrin polymer and measuring method for water contamination level using the same
ATE513858T1 (en) 2004-09-10 2011-07-15 Nat Ct For Scient Res Sdemokritoss Neapoleos & PER-6-GUANIDINO-, -AMINOALKYLAMINO- AND - GUANIDINO-ALKYLAMINO-CYCLODEXTRINS, METHOD FOR THE SYNTHESIS AND THEIR USE FOR COMPACTING DNA AND INTERCELLULAR DELIVERY
GR1004952B (en) * 2004-09-10 2005-07-28 Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων "Δημοκριτος" New per-6-gaunidino-, -aminoalkylamino- and -guanidinoalkylamino-cyclodextrins, methods of their synthesis and their use for the compaction of dna
FR2878853B1 (en) 2004-12-07 2007-03-16 Biocydex Soc Par Actions Simpl METHOD FOR OBTAINING A FLUORESCENT COMPLEX, COMPLEX OBTAINED AND USE
WO2006075580A1 (en) 2005-01-13 2006-07-20 National University Corporation Nagoya Institute Of Technology Antibacterial substances injuring bacterial cell membarane and methods of using the same
CA2596026A1 (en) * 2005-01-28 2006-08-10 Pinnacle Pharmaceuticals, Inc. .beta.-cyclodextrin derivatives as antibacterial agents
WO2007009265A1 (en) 2005-07-22 2007-01-25 The Governors Of The University Of Alberta Tec Edmonton NOVEL β-CYCLODEXTRIN-BASED MOLECULES AND DRUG DELIVERY COMPOSITIONS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1846006A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2061445A2 (en) * 2006-08-30 2009-05-27 Research Foundation of the City University of New York Antimicrobial compositions
JP2010502613A (en) * 2006-08-30 2010-01-28 リサーチ ファウンデーション オブ シティ ユニバーシティ オブ ニューヨーク Antibacterial composition
EP2061445A4 (en) * 2006-08-30 2011-07-06 Univ City New York Res Found Antimicrobial compositions
WO2013027040A1 (en) * 2011-08-22 2013-02-28 Isis Innovation Limited Cyclic oligosaccharides for use in the treatment and prevention of bacterial infection
US9963518B2 (en) 2011-08-22 2018-05-08 Oxford University Innovation Limited Cyclic oligosaccharides for use in the treatment and prevention of bacterial infection
WO2018051903A1 (en) 2016-09-13 2018-03-22 国立大学法人名古屋工業大学 Sugar derivative or salt thereof, and antibacterial agent or antibacterial activity enhancer using same
KR101967326B1 (en) * 2017-10-30 2019-08-13 한남대학교 산학협력단 Cationic cyclodextrin derivatives and drug delivery system using thereof
TWI774079B (en) * 2020-10-05 2022-08-11 逢興生物科技股份有限公司 Use of cyclodextrin for manufacturing a composition for inhibiting growth of oral bacteria

Also Published As

Publication number Publication date
CN101151037A (en) 2008-03-26
ZA200706191B (en) 2010-05-26
IL184844A0 (en) 2008-06-05
RU2007133709A (en) 2009-03-20
WO2006083678A3 (en) 2006-12-14
EP1846006A4 (en) 2011-04-20
US20110071108A1 (en) 2011-03-24
EP1846006A2 (en) 2007-10-24
MX2007010129A (en) 2007-11-16
US7737132B2 (en) 2010-06-15
KR20070101347A (en) 2007-10-16
US20060199785A1 (en) 2006-09-07
JP2008528761A (en) 2008-07-31
CA2596026A1 (en) 2006-08-10
AU2006211173A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
WO2006083678A2 (en) β-CYCLODEXTRIN DERIVATIVES AS ANTIBACTERIAL AGENTS
US10201587B2 (en) Methods of inhibiting and treating biofilms using glycopeptide antibiotics
CN110123801B (en) Application of multi-arm AIE molecule in preparation of antibacterial drug and antibacterial drug
US6498238B1 (en) Glycopeptide antibacterial compounds, compositions containing same and methods of using same
EP3903827A1 (en) Use of rifamycin-quinolizidone coupling molecule and pharmaceutically acceptable salt thereof
Waitz et al. Chemotherapeutic evaluation of 5-episisomicin (Sch 22591), a new semisynthetic aminoglycoside
WO2009058327A1 (en) Cyclodextrin derivatives as potentiators for antibiotics
CN107073124A (en) The antimicrobial of synergy
JP2017521432A (en) N- (hydrophobic substituted) vancosaminyl [Ψ [C (═NH) NH] Tpg4] vancomycin and [Ψ [CH2NH] Tpg4] vancomycin
EP2317998B1 (en) Fulvic acid and antibiotic combination
WO2001081373A2 (en) Glycopeptide antibacterial compounds and methods of using same
KR20150003222A (en) Use of delphinidin against staphylococcus aureus
EP1551422A1 (en) Carbohydrate based anti-bacterials
CN1767821A (en) Drug composition with antimicrobial activity
CN113082026A (en) Application of artemisinin derivative in preparation of polymyxin antibacterial synergist
Smith et al. Daptomycin versus vancomycin treatment for Staphylococcus aureus bacteremia in a murine model
US11998560B2 (en) Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against multidrug and extensively drug-resistant Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates
CN114028418B (en) Antibacterial composition containing chitosan oligosaccharide and application thereof
US6589993B2 (en) Treating vancomycin-intermediates and multiresistant staphylococci infection with thiamphenicol or a salt thereof
CN109069474B (en) Synergistic tulathromycin
CN106673989A (en) Pharmaceutical composition as well as preparation method and application thereof
US20210290648A1 (en) Potentiation of B-Lactam Antibiotics and B-Lactam/B-Lactamase Inhibitor Combinations Against Multidrug and Extensively Drug-Resistant Pseudomonas Aeruginosa Using Non-Ribosomal Tobramycin-Cyclam Conjugates
CN116063444A (en) Application of antibacterial peptide CATHPb1 synergistic antibiotics in preparation of antibacterial agent
Hashizume et al. Penetration of imipenem and other antibiotics into inflammatory exudate and their efficacy in pseudomonas infection in the rat granuloma pouch model
CN114989165A (en) Compound or composition for resisting retention bacteria and biofilm bacteria and application thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680010155.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006211173

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2596026

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 184844

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007553231

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2006733927

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006211173

Country of ref document: AU

Date of ref document: 20060127

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 3008/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/010129

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020077019399

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 561140

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007133709

Country of ref document: RU